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Spontaneous CD8 T-cell responses occur in growing tumors but are
usually poorly effective. Understanding the molecular and cellular
mechanisms that drive these responses is of major interest as they
could be exploited to generate a more efficacious antitumor im-
munity. As such, stimulator of IFN genes (STING), an adaptor mole-
cule involved in cytosolic DNA sensing, is required for the induction
of antitumor CD8 T responses in mouse models of cancer. Here, we
find that enforced activation of STING by intratumoral injection of
cyclic dinucleotide GMP-AMP (cGAMP), potently enhanced antitu-
mor CD8 T responses leading to growth control of injected and
contralateral tumors in mouse models of melanoma and colon can-
cer. The ability of cGAMP to trigger antitumor immunity was further
enhanced by the blockade of both PD1 and CTLA4. The STING-depen-
dent antitumor immunity, either induced spontaneously in growing
tumors or induced by intratumoral cGAMP injection was dependent
on type I IFNs produced in the tumor microenvironment. In response to
cGAMP injection, both in the mouse melanoma model and an ex vivo
model of cultured human melanoma explants, the principal source of
type I IFNwas not dendritic cells, but instead endothelial cells. Similarly,
endothelial cells but not dendritic cells were found to be the principal
source of spontaneously induced type I IFNs in growing tumors. These
data identify an unexpected role of the tumor vasculature in the initi-
ation of CD8 T-cell antitumor immunity and demonstrate that tumor
endothelial cells can be targeted for immunotherapy of melanoma.
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Metastatic melanoma is a highly aggressive cancer with a fastincreasing incidence worldwide. Unless diagnosed early and
surgically resected, the disease becomes metastatic and life threaten-
ing. Both chemotherapy and irradiation are ineffective. Novel thera-
pies that target oncogenic drivers have brought some improvements,
but tumor cells escape regularly (1). Melanoma is a prototypical im-
munogenic tumor, as shown by the occurrence of spontaneous CD8
T-cell responses that drive tumor regressions and by the identification
of CD8 T cells that recognize melanoma antigens (2, 3). Although
many immunotherapeutic strategies have been developed to induce
such responses, clinical efficacies have been poor. More recently,
“checkpoint blockade” therapies that target T-cell–inhibitory pathways
mediated by CTLA4 (4) and PD1 (5) have yielded encouraging
clinical results and demonstrated that spontaneous CD8 T-cell re-
sponses in tumors can be boosted to treat melanoma.
The mechanisms that drive spontaneous antitumor immune
responses are poorly understood. Type I IFNs (IFN-α and IFN-β)
may play a role as the expression type I IFN-related genes in primary
melanoma has been associated with spontaneous tumor regressions
(6) and correlated to the tumor infiltration by specific CD8+ T cells
(6, 7). Furthermore, the lack of type I IFN signaling or IFN-β ex-
pression inhibited the generation of tumor-specific CD8 T cells and
accelerated tumor growth in a murine melanoma model (7–9).
Type I IFNs are typically induced upon recognition of nucleic
acids in intracellular compartments. Several cytosolic DNA recep-
tors have been identified and include DNA-dependent activator
of IFN-regulatory factors (DAI) (10), gamma-interferon-inducible
protein-16 (IFI16) (11), and the helicase DEAD (Asp-Glu-Ala-Asp)
box protein 41 (DDX41) (12). These cytosolic receptors trigger
IFN-β production via a signaling cascade that involves the master
adaptor molecule stimulator of IFN genes (STING), which binds to
tank-binding kinase 1 (TBK1) and induces phosphorylation of
the interferon regulatory factor 3 (IRF3) (13). STING associates
weakly to dsDNA (14) but strongly binds the endogenous cyclic
dinucleotide GMP-AMP (cGAMP) synthesized by the cGMP-
AMP synthase (cGAS) (15, 16).
Recently, spontaneous STING activation was found to be re-
quired for the spontaneous induction of antitumor immunity (17).
Activation of STING occurred via tumor DNA-dependent cGAS
activation and generation of endogenous cGAMP (17, 18). However,
the cellular mechanism underlying this response and whether this
mechanism could be exploited to generate more efficient antitu-
mor immune responses is currently unknown.
Here, we show that intratumoral injection of exogenous cGAMP
enhanced STING activation and strongly promoted the generation
of antitumor CD8 T-cell responses leading to efficient growth
control of injected and contralateral tumors. This response was
dependent on IFN-β produced by tumor endothelial cells. In fact,
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endothelial cells were found to be the principal producers of type I
IFN in response to both spontaneous and enforced STING acti-
vation, suggesting a role of the tumor vasculature in the initiation
of antitumor immunity.
Results
Intratumoral Injection of cGAMP Promotes the Induction of CD8 T-Cell
Responses and Efficiently Delays Growth of Injected Tumors. Initially,
we established a mouse melanoma model to study STING-
dependent induction of antitumor immunity. We engrafted
B16F10 melanoma cells in wild-type mice or STING-deficient
mice (STINGgt/gt) and measured tumor-infiltrating CD8 T cells
as well as tumor size. CD8 T cells spontaneously infiltrating tu-
mors were drastically reduced and tumor growth was accelerated
in STINGgt/gt compared with WT mice (Fig. 1 A and B). Because
this spontaneous STING-dependent CD8 T-cell response was
insufficient to control the growth of tumors, we sought to in-
vestigate whether the intratumoral injection of the STING ago-
nist cGAMP could be used therapeutically to enhance this
response. We injected cGAMP into B16F10 melanoma at day 5
and day 10 after engraftment and measured CD8 T-cell in the
tumors along with tumor size. Compared with control injected
tumors, tumors injected with cGAMP showed a mean of fourfold
increase of CD8 T cells in the tumor microenvironment (Fig. 1A)
along with a significant delay in tumor growth (Fig. 1B). These ef-
fects were completely abolished in STINGgt/gt mice (Fig. 1 A and B).
cGAMP also increased tumor-infiltrating CD8 T-cell numbers and
delayed tumor growth when injected into engrafted melanoma
derived from Tyr::N-ras(Q61K)INK4A−/− mice (19) (Fig. S1) and
B-raf(V600E/+) PTEN−/− CDKN2A−/− mice (20) (Fig. S1). Tumor-
infiltrating CD8 T cells displayed an effector phenotype (CD44hi
CD62Llow) and were able to produce IFNγ. Compared with con-
trol-injected tumors, higher numbers of perforin-expressing CD8 T
cells were found in cGAMP-injected tumors (Fig. S2) suggesting the
induction of cytotoxic effector CD8 T cells. These tumor-infiltrating
CD8 T cells appeared to be tumor antigen-specific as OVA specific
CD8 T cells were detected in the tumors when OVA was used as a
model antigen expressed by tumors (Fig. S2). Thus, intratumoral
cGAMP promotes the generation of Ag-specific cytotoxic CD8
T cells that infiltrate tumors. Interestingly, intratumoral cGAMP
injection also induced high numbers of infiltrating CD4 T cells in
B16F10, Tyr::N-ras(Q61K)INK4A−/−, and B-raf(V600E/+) PTEN−/−
CDKN2A−/− melanoma (Fig. S3). Intratumoral cGAMP im-
proved survival of tumor-bearing mice as shown by the fact that
31% of WT mice treated with intratumoral cGAMP survived up
to 3 mo, whereas control mice all died within 3 wk (Fig. 1C). The
antitumor efficacy of intratumoral cGAMP was further
enhanced by concomitant blockade of CTLA4 and PD1. In
fact, the anti-CTLA4+anti-PD1 combo increased the antitumor
activity of cGAMP in a dose-dependent manner (Fig. S4) and led
to a complete inhibition of tumor growth for up to 23 d post-
implantation (Fig. 1D). These data indicate that enforced STING
activation by intratumoral cGAMP injection can potently increase
the generation of Ag-specific effector CD8 T cells infiltrating the
tumor and efficiently control its growth.
Intratumoral STING Activation Leads to Systemic CD8 T-Cell–Mediated
Antitumor Immunity That Controls the Growth of Distant Tumors. We
next investigated whether, via the induction of CD8 T-cell re-
sponses, intratumoral injections of cGAMP could induce systemic
antitumor immunity. First, mice bearing skin tumors that had been
injected with cGAMP, received i.v. B16F10 tumor cells to induce
lung metastases. Ten days later, mice were killed and the number
of melanoma metastases was counted in the lungs. Intratumoral
injection of cGAMP potently reduced the number of lung me-
tastases (Fig. 2A), suggesting the induction of systemic immunity
that inhibits metastasis formation. To confirm this, we engrafted
B16F10 tumors into opposite flanks of the same mouse followed
by treatment of only one tumor while leaving the contralateral one
untreated. We found that intratumoral cGAMP treatment not
only delayed the growth of injected tumors, but also delayed the
growth of contralateral tumors (Fig. 2B). This effect was not
limited to B16 melanoma, as intratumoral injection of cGAMP
also delayed the growth of injected and contralateral MC38 colon
tumor cells implanted into the skin (Fig. S5). Antibody-mediated
CD8 T-cell depletion completely abolished the effect of cGAMP
on contralateral tumor (Fig. 2B) but only had a partial effect on
cGAMP-injected tumors (Fig. 2C). These data suggest that
intratumoral cGAMP induces CD8 T-cell priming that drive sys-
temic antitumor immunity controlling local and distant tumor
growth. Interestingly, the local antitumor response to cGAMP is
only partially dependent on these CD8 T cells, suggesting that
additional mechanisms account for a direct antitumor activity.
The Antitumor Activity Induced by STING Is Dependent on Type I IFN
Signaling. Because STING has been associated with type I IFN
induction (21) we next sought to investigate the role of type I
IFNs in mediating the antitumor CD8 T-cell response induced by
cGAMP. As previously described (17), low levels of type I IFNs
were spontaneously induced by STING signaling in growing tu-
mors of WT mice as we detected the expression of the type I
IFN-inducible genes Mx2, Irf7, and Isg15 that were abolished
in STINGgt/gt mice (Fig. S6). Lack of type I IFN signaling in
IFNAR−/− mice not only abolished the type I IFN signature in
A
WT
STIN
Gg
t/gt
0.53
0.095
cGA
MP
-inj
C
D
8
CD3
Ctr
l-in
j
0.46 1.58
0.14
Non
 inj
0.10
Tu
m
or
 v
ol
um
e 
(m
m
3 )
B C D
0
50
100
%
 s
ur
vi
va
l
Days 
1000
2000
3000
WT 
WT 
STING
gt/gt 
WT 
*
*
*
0 10 20 30 40 80 120
Days
0
0
1000
2000
3000
Tu
m
or
 v
ol
um
e 
(m
m
3 )
Days
****
**
%
 o
f C
D
8+
 T
 c
el
ls
  (
da
y 
15
)
**
0
1
2
3
4
*
**
 WT
 STINGgt/gt WT 
WT  
5 10 150
0
non
 inj
Ctrl
-inj
cGA
MP-
inj
5 10 15 20
Ctrl
-inj
cGA
MP-
inj
STING
gt/gt 
STING
gt/gt 
STING
gt/gt 
STINGgt/gt
cGA
MP
-inj
Ctr
l-in
j
Non
 inj
Saline
αCTLA4/αPD1
Saline
αCTLA4/αPD1
Ctrl
-inj
cGA
MP-
inj
***
*
*
*
*
*
Fig. 1. Intratumoral cGAMP promotes CD8 T-cell responses and efficiently delays growth of injected tumors. (A–C) C57BL6 or STINGgt/gt mice bearing
established s.c. B16F10 tumors were either left untreated (non inj), injected intratumorally with cGAMP (cGAMP-inj), or injected with Lipofectamine
alone (Ctrl-inj) at day 5 and day 10 postengraftment. Depicted are: (A) CD3+CD8+ T cells infiltrating tumors at day 15 postengraftment, measured by
flow cytometry of tumor single cell suspensions. Representative plots are given (Left). Each symbol represents a separate mouse (Right). *P < 0.05, **P < 0.01,
***P < 0.001 by unpaired t test. (B) Tumor growth over time. Data are shown as mean tumor volume ± SEM of 5–6 mice per group, *P < 0.05, **P < 0.01 by
two-way ANOVA. (C) Mouse survival monitored over time. Analysis include 5–16 mice per group, **P < 0.01, ****P < 0.0001 by log rank (Mantel Cox) test.
(D) Mice bearing s.c. B16 tumors were treated as described above in the setting of anti-CTLA4 and anti-PD1 antibody treatment. Graph depicts tumor growth
over time. Data are shown as mean tumor volume ± SEM of seven mice per group. *P < 0.05, **P < 0.01 by two-way ANOVA.
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tumors, but also abrogated CD8 T-cell responses in the tumors
(Fig. S6). We then sought to investigate whether the same type I
IFN-dependent mechanism would underlie the strong antitumor
CD8 T-cell responses observed following cGAMP injection.
First, we measured type I IFN activity induced by intratumoral
cGAMP. Strong type I IFN activity was detected starting 1 h after
injection, peaking between 2 h and 4 h, and declining thereafter
(Fig. 3A). mRNA expression analysis 4 h after injection revealed
expression of Ifn-β1 but not of Ifn-α genes such as Ifn-α2, Ifn-α5,
and Ifn-α6 (Fig. 3B), indicating that intratumoral STING activation
triggers an early type I IFN activity via the induction of Ifn-β1 ex-
pression. We then assessed the role of IFN-β in the local and sys-
temic antitumor activity induced by cGAMP. Treatment of WT
mice with blocking anti-IFNAR antibodies or the use of IFNAR−/−
mice to block IFNAR signaling completely abolished intratumoral
CD8 T-cell numbers and antitumor activities in both injected and
contralateral tumors (Fig. 3 C and D). Interestingly, despite being
only partially CD8 T-cell dependent, the local antitumor activity
induced by cGAMP injection was entirely mediated by type I IFNs.
To test whether IFN-β expression had a direct inhibitory activity on
the growth of B16 tumor cells, we generated extracts from cGAMP-
injected tumors and tested their ability to block the growth of B16
tumor cells with or without neutralizing antibodies to IFNAR.
These tumor extracts were indeed able to block the growth of B16
cells in a type I IFN-dependent manner (Fig. S7), a finding that is
consistent with previous reports showing that type I IFNs block
proliferation and induce apoptosis of B16 cells (22, 23). Together
these data indicate that IFN-β is required for the generation of
tumor-infiltrating CD8 T cells and for the antitumor activity in-
duced by intratumoral cGAMP.
Endothelial Cells Are the Principal IFN-β Producers in Response to
Therapeutic STING Activation in Tumors. To identify the cell type
responsible for the STING-mediated induction of IFN-β production
in the tumor microenvironment, we performed intracellular IFN-β
staining of tumor-cell–derived single cell suspensions generated af-
ter intratumoral cGAMP injection. Flow cytometry analysis revealed
a small population of IFN-β–producing cells in the tumor micro-
environment of engrafted wild-type mice that was not present in
tumors engrafted in STING-deficient mice (Fig. 4A). Pheno-
typical analysis of IFN-β–producing cells revealed that IFN-β was
produced by a homogeneous population that did not express
lineage markers for T cells, B cells, NK cells, DC, monocyte/
macrophages nor neutrophils (CD3, CD19, NKp46, CD11C,
CD11b, and Ly6G, respectively) (Fig. 4B). IFN-β–producing
cells expressed low levels of the hematopoietic marker CD45
and, surprisingly, expressed the specific endothelial cell markers
CD31, VE-Cadherin, and VEGFR-2 (Fig. 4B). To confirm that
endothelial cells are the principal target of STING activation in
the tumor microenvironment, we performed immunofluorescent
staining for IFN-β on cGAMP-injected tumors engrafted in wild-
type mice or STING-deficient mice. IFN-β was always found to be
associated with the VEGFR2+ and CD31+ tumor endothelial
cells (Fig. 4C and Fig. S8) and not produced by CD45+ infiltrating
immune cells including CD11c+ dendritic cells (DCs) (Fig. 4C).
Importantly, IFN-β was not detected in cGAMP-injected tumors
engrafted in STINGgt/gt mice (Fig. 4C and Fig. S8). Our data
suggest that endothelial cells and not DCs are the principal type
IFN-producing cell type in the tumor in response to STING ac-
tivation. These data were confirmed by the finding that the IFN-β
induction in response to intratumoral cGAMP was unaltered in
CD11c-depleted mice (Fig. S9). More specifically, we confirmed
that plasmacytoid dendritic cells (pDCs), which are the principal
type I IFN-producing cells during antiviral immune responses,
were not involved in the antitumoral activity induced by cGAMP
as inhibition of tumor growth was retained upon pDC depletion in
hBDCA2-DTR mice (Fig. S9). Thus, our data identify tumor
endothelial cells as the principal type I IFN producers in response
to therapeutic STING activation by cGAMP.
To determine whether cGAMP could also activate STING in
human melanoma, we injected cGAMP into freshly resected
melanoma skin metastases. Intratumoral cGAMP induced high
levels of IFN-β expression in skin melanoma metastases compared
with control injected melanoma (Fig. 4D). Immunofluorescence
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stainings confirmed that IFN-β was expressed predominantly by
CD31+ endothelial cells in the tumor microenvironment. Thus,
intratumoral cGAMP can induce type I IFNs by the human tumor
vasculature (Fig. 4E).
Endothelial Cells Produce High Level of Type I IFNs upon STING
Activation. To evaluate the capacity of endothelial cells to pro-
duce type I IFNs, we performed in vitro stimulation of murine
endothelial cells with cGAMP or CpGs in comparison with total
CD11c+ DCs, which have previously been suggested to be the
main IFN producers in the tumor microenvironment (17). We
found stronger type I IFN activity in endothelial cells stimulated
by cGAMP compared with DCs (Fig. 5A). By contrast, type I IFN
activity was higher in DCs stimulated with CpG compared with
endothelial cells (Fig. 5A). Because cytosolic transfer of extracel-
lular tumor-derived DNA can trigger activation of STING (17),
we tested whether it could also trigger type I IFN production in
endothelial cells and DCs. Lipofected tumor DNA was indeed a
potent inducer of type I IFN activity via STING activation of
endothelial cells but not DCs (Fig. 5 A and B). IFN-β and IFN-α
mRNA expression analysis confirmed that STING activation in-
duced a predominant IFN-β expression in endothelial cells com-
pared with DCs, whereas IFN-α mRNA was hardly detectable in
both cell types (Fig. 5C). Although poorly responding to STING
activation by cGAMP, purified pDCs expressed high levels of IFN-α
and IFN-β mRNA upon stimulation with CpG (Fig. 5C), consistent
with their specialized function as type I IFN producers in response
to endosomal TLR activation. Therefore, in vitro, endothelial cells
appear to produce higher amounts of IFN-β in response to STING
activation compared with DCs.
Endothelial Cells Are the Principal IFN-β Producers in Response to
Spontaneous STING Activation in Tumors. Next we sought to de-
termine whether endothelial cells also represent the main source
of spontaneous type I IFN expression in growing tumors. mRNA
expression analysis revealed that Ifn-β1 was spontaneously in-
duced in the tumors as early as day 3 after tumor engraftment,
reaching maximal expression levels at day 5 (Fig. 6A). This time
point was also characterized by the presence of a large number of
CD45- CD31+ VEGFR2+ endothelial cells in the tumor, whereas
CD45+ immune cells including CD8 T cells and CD11c+ DCs
appeared later (Fig. 6 B and C). Immunofluorescence staining
identified a rare population of IFN-β–expressing cells (Fig. S8),
which always costained with endothelial cell markers and was
completely absent in tumors of STING-deficient mice (Fig. 6D).
These data suggest that tumor endothelial cells are also a main
source of spontaneous type I IFN expression in the tumor mi-
croenvironment. Endothelial cell-derived type I IFNs preceded
the infiltration of CD11c+ DCs and CD8 T cells in the tumor
microenvironment, suggesting their role in initiating the antitumor
response via type I IFN production.
Discussion
Our study demonstrates that intratumoral injection of cGAMP
induces potent STING activation in the tumor microenviron-
ment and thereby inhibits tumor growth by promoting natural
CD8 T-cell responses against the tumor. The cGAMP-induced
antitumor activity was found to be mediated by the STING-driven
induction of IFN-β in the tumor microenvironment. Interestingly,
tumor endothelial cells were the main producer of IFN-β in re-
sponse to cGAMP injection in both mouse and human. Endothelial
cells were also found to be the main source of spontaneous IFN-β
production in growing tumors. Together these data indicate that
the tumor vasculature plays a key role in the initiation of sponta-
neous and therapeutic CD8 T-cell immunity against the tumor via
STING-dependent induction of type I IFNs.
Type I IFNs play a multifaceted role in the induction of antitu-
mor immunity. First, type I IFNs enhance tumor-specific CD8
T cells priming by promoting the recruitment and activation of DCs
at the tumor site (7, 8). Accordingly, type I IFNs were found to
increase the number of DCs in the microenvironment of cGAMP-
injected tumors and to stimulate DC maturation as we detected a
higher levels of CD80 and CD86 in DCs in lymph nodes draining
cGAMP-injected tumors (Fig. S10). Second, type I IFNs may in-
crease CD8 T-cell infiltration into cGAMP-injected tumors (6)
and directly promote their survival and proliferation in the tumor
microenvironment (24). However, our data suggest that the potent
local antitumor efficacy is not explained by increased CD8 T-cell
infiltration of cGAMP-injected tumor but rather by a direct in-
hibitory effect of type I IFNs on the tumor itself (22, 23).
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Fig. 3. Intratumoral cGAMP induces expression of
IFN-β that drives local and systemic antitumor im-
munity. (A and B) Mice bearing 5-d established s.c.
B16F10 tumors were treated by i.t. injection of
cGAMP (cGAMP-inj) or Lipofectamine alone (Ctrl-inj).
Depicted are: (A) Type I IFN activity in tumor extracts
at the indicated time after treatment. (B) Ifn-β1, Ifn-
α2, Ifn-α5, and Ifn-α6 mRNA expression in tumors
4 h after treatment. Each symbol represents an in-
dependent mouse, **P < 0.001 by unpaired t test.
(C and D) B16F10 cells were implanted s.c. into op-
posite flanks of WT or IFNAR−/− mice followed by i.t.
injection of cGAMP (cGAMP-inj) or Lipofectamine
alone (Ctrl-inj) in only one tumor. WT mice were also
treated with a neutralizing αIFNAR antibody. Depic-
ted are: (C) CD3+CD8+ T cells infiltrating tumors at
day 15 postengraftment, measured by flow cytom-
etry of tumor single cell suspensions. Representative
plots are given (Upper); each symbol represents an
independent mouse (Lower). *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001 by unpaired t test.
(D) Tumor growth over time of injected and contra-
lateral tumors. Data are given as the mean tumor
volume ± SEM with n = 5, representative of two in-
dependent experiments, *P < 0.05, **P < 0.01, ***P <
0.001 by two-way ANOVA.
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DCs are typically believed to be the main source of type I IFN
during immune response. Unexpectedly, our study identifies en-
dothelial cells and not DCs as the principal IFN-producing cell in
response to both spontaneous and enforced STING activation in
the tumor microenvironment. One reason for this is that endo-
thelial cells possess an enhanced capacity to produce type I IFNs in
response to STING activation compared with DCs. Confirming our
data, previous studies found that in vitro-stimulated endothelial cells
express more type I IFNs than other immune cells such as macro-
phages following STING activation by viruses (25). Another reason
for the preferential type I IFN production by endothelial cells may
be related to their relative abundance in the tumor compared with
tumor-infiltrating immune cells. Indeed, at the time of intratumoral
cGAMP injection, endothelial cells in the tumor microenviron-
ment are fourfold more abundant than DCs. Interestingly, we
found exclusive expression of IFN-β but did not detect any IFN-α
in the tumor microenvironment. This may be related to the weak
capacity of endothelial cells to produce IFN-α upon STING
activation, but may also be related to the fact that IFN-α expres-
sion requires prior IFN-β–mediated up-regulation of IRF7 (26).
In spontaneously growing tumors IFN-β is also induced early at
the time of tumor vasculature formation, before the infiltration of
immune cells. Here, type I IFNs produced by endothelial cells is
necessary for the infiltration and activation of cross-presenting DCs
and CD8 T cells in the tumor microenvironment by the mecha-
nisms described above. A likely source of endogenous STING li-
gands is tumor DNA or tumor-derived cGAMP, although it is
unclear how they can spontaneously reach intracellular compart-
ments of endothelial cells. Tumors may package DNA in apoptotic
bodies and transfer it to endothelial cells (27), where it activates
STING upon cGAS-mediated conversion to cGAMP (15, 16).
Another possibility is that tumor cGAMP is directly transferred to
endothelial cells via connexin-mediated channels, as this has been
previously suggested (28).
Intratumoral STING activation by cGAMP and potentially
other ligands may be an attractive candidate for antitumor therapy
of metastatic melanoma patients. The efficacy of intratumoral
cGAMP is strongly enhanced by combination with anti-CTLA4 and
anti-PD1 therapy, the currently most potent immunotherapeutic
approach in melanoma (29). Intratumoral cGAMP activation is also
effective in the MC38 model of colon carcinoma, suggesting that
other tumors can be treated by enforced intratumoral STING ac-
tivation. These data were confirmed by the finding that local tumor
radiotherapy of MC38 tumors can be enhanced by intratumoral
cGAMP injection (18).
Our data identify a key role of the tumor vasculature arising in
growing tumors in the shaping of CD8 T-cell–mediated antitumor
immunity. This finding raises the question about the effect of
antiangiogenic therapies (30), which are being developed and
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Fig. 4. Endothelial cells represent the main IFN-β producers upon intra-
tumoral cGAMP injection in mouse and human. (A–C) WT or STINGgt/gt mice
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cGAMP plus Brefeldin A. Tumors were harvested after 5 h for flow cytometry
and confocal microscopy analysis. (A) Intracellular IFN-β detection in tumor
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as shown in A compared with nonIFN-β–producing cells (gray line). Data are
representative of at least three independent experiments. (C) IFN-β expression
on CD31 or VEGFR2 cells in tumor cryosections derived fromWT (a–c and e–g) or
STINGgt/gt mice (d and h). (Scale bar, 100 μm.) (D and E) Resected human
melanoma skin metastases were injected with 2′3′-cGAMP (cGAMP-inj) or
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(only in E) for 5 h before analysis. Depicted are: (D) Quantitative real-time
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0.01 by unpaired t test. (E) Confocal microscopy of IFN-β and CD31 stained on
cryosections derived from treated tumor explants. (Scale bar, 100 μm.)
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Fig. 5. Endothelial cells are specialized in producing large quantities of
IFN-β in response to STING activation. (A) MS-1 endothelial cells, B16 tumor
cells, and splenic CD11c+ DCs were stimulated overnight with cGAMP (5 μg/mL),
tumor DNA (3 μg/mL), both complexed with Lipofectamine or with CpG-B (1 μg/
mL). Type I IFN activity was measured in the culture supernatant. Data are
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deficient (shSTING) or control (shControl) MS-1 endothelial cells were stimulated
overnight with increasing concentrations of tumor DNA complexed with Lip-
ofectamine. Type I IFN activity was measured in the culture supernatant. Data
are expressed as mean ± SD of two independent experiments. **P < 0.01, ***P <
0.005 by unpaired t test. (C) MS-1 endothelial cells, spleen CD11c+ DCs, or pu-
rified spleen pDCs were activated for 5 h as described inA. Ifn-β1 and Ifn-α2 gene
expression were determined by quantitative real-time PCR. Data are shown as
fold induction over nonstimulated cells. *P < 0.05, **P < 0.01, by unpaired t test.
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considered to be used in combination with immune-based thera-
pies, on antitumor immunity.
In conclusion, our study identifies STING to be the central
molecular driver of spontaneous antitumor immune responses that
can be exploited to generate potent antitumor immunity. We also
identify endothelial cells as the principal cellular target of STING
activation, uncovering an unexpected role of the tumor vasculature
in the control of tumor growth via the initiation of antitumor im-
munity in melanoma.
Materials and Methods
Study Approval. These experiments were approved by the Institutional Ani-
mal Care and Use Committee of the University of Lausanne.
Tumor Model and Treatment. Mice were injected s.c. with 5 × 105 B16 mel-
anoma cells. At 5 d after implantation, 10 μg of cGAMP complexed with
Lipofectamine 2000 was injected into engrafted tumors. Tumor size was
measured every 2 d using a caliper. Materials and methods are described in
greater detail in Supporting Information.
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Fig. 6. Endothelial cells are the principal IFN-β producers in response to spontaneous STING activation in tumors. B16F10 melanoma cells were implanted into the
flank ofWT or STINGgt/gt mice. (A) Time course analysis of spontaneous Ifn-β1mRNA expression in tumors after implantation inWTmice. Data represent the mean±
SEM of at least four independent mice. (B) Detection by flow cytometry of endothelial cells (VEGFR2+ CD31+ gated on CD45lo/neg), CD8 T cells (CD3+ CD8+), and
DCs (CD45+ CD11c+) in single cell suspensions derived from tumors over time after their implantation. Data are expressed asmean ± SD of at least four independent
mice. (C) Representative flow cytometry plot is shown. (D) Detection of spontaneous IFN-β production in tumors. Data show representative confocal microscopy
images of 5-d-old tumors harvested from WT (a–c) or STINGgt/gt mice (d) and stained for IFN-β and CD31. (Scale bar, 100 μm.)
Demaria et al. PNAS | December 15, 2015 | vol. 112 | no. 50 | 15413
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
